All In Biotech

Drug Trial Radar · NCT01968031

A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/Day as Treatment for Subjects With Moderate to Severe Parkinson's Disease

Last checked: Nov 20, 2026Latest source record: Apr 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 613 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

613

Actual

Start

Oct 2013

Primary completion

Oct 2016

Study completion Oct 2016

Sponsor

Lead sponsor
Kyowa Kirin Co., Ltd.Industry
Sponsor type
Industry
Collaborators
Kyowa Hakko Kirin Pharma, Inc.
First posted
Oct 23, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to assess the efficacy and safety of oral Istradefylline (KW-6002) in patients with moderate to severe Parkinson's Disease. While on this study, participants will continue to take their usual, prescribed, stable regimen of Levodopa/Carbidopa or Levodopa/Benserazide therapy plus adjunct Parkinson's medications. Patients will be randomized 1:1:1 to receive either Istradefylline 20 mg per day, or Istradefylline 40 mg per day or an equivalent placebo. Patients will be treated for a 12 week period to demonstrate the effectiveness of Istradefylline in improving Parkinson's disease symptoms (referred to as improvement in patient OFF time) and that Istradefylline has an acceptable safety profile in this group.

Conditions

  • Idiopathic Parkinson's Disease

Interventions

  • Istradefylline 40 mgDrug

    Istradefylline 40 mg and placebo

  • Istradefylline 20 mgDrug

    Istradefylline 20 mg and placebo

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the Total Hours of Awake Time/Day Spent in the OFF State at Week 12Time frame: Baseline, Week 2, Week 6, Week 10 and Week 12.

Locations

89 sites in 8 countries. Site status is shown where the registry gives one.

  • Kyowa PD Site

    Phoenix, Arizona

  • Kyowa PD Site

    Sun City, Arizona

  • Kyowa PD Site

    Tucson, Arizona

  • Kyowa PD Site

    Fountain Valley, California

  • Kyowa PD Site

    Irvine, California

  • Kyowa PD Site

    Los Angeles, California

  • Kyowa PD Site

    Oxnard, California

  • Kyowa PD Site

    Pasadena, California

  • Kyowa PD Site

    Reseda, California

  • Kyowa PD Site

    Sunnyvale, California

  • Kyowa PD Site

    Torrance, California

  • Kyowa PD Site

    Englewood, Colorado

  • Kyowa PD Site

    Danbury, Connecticut

  • Kyowa PD Site

    Boca Raton, Florida

  • Kyowa PD Site

    Jacksonville, Florida

  • Kyowa PD Site

    Panama City, Florida

  • Kyowa PD Site

    Port Charlotte, Florida

  • Kyowa PD Site

    Tampa, Florida

  • Kyowa PD Site

    Atlanta, Georgia

  • Kyowa PD Site

    Augusta, Georgia

  • Kyowa PD Site

    Chicago, Illinois

  • Kyowa PD Site

    Chicago, Illinois

  • Kyowa PD Site

    Des Moines, Iowa

  • Kyowa PD Site

    Kansas City, Kansas

  • Kyowa PD Site

    Baltimore, Maryland

  • Kyowa PD Site

    Boston, Massachusetts

  • Kyowa PD Site

    West Bloomfield, Michigan

  • Kyowa PD Site

    Minneapolis, Minnesota

  • Kyowa PD Site

    St Louis, Missouri

  • Kyowa PD Site

    Albany, New York

  • Kyowa PD Site

    New York, New York

  • Kyowa PD Site

    New York, New York

  • Kyowa PD Site

    Asheville, North Carolina

  • Kyowa PD Site

    Durham, North Carolina

  • Kyowa PD Site

    Cincinnati, Ohio

  • Kyowa PD Site

    Cleveland, Ohio

  • Kyowa PD Site

    Toledo, Ohio

  • Kyowa PD Site

    Philadelphia, Pennsylvania

  • Kyowa PD Site

    Charleston, South Carolina

  • Kyowa PD Site

    Dallas, Texas

Showing 40 of 89 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.